CFDA approval isn't due until at least September I believe (18 month minimum?) so I suspect it'll be bumpy until then on low volume. Of note Sihuan pharma Meng's company has taken a real beating over the last few months. China is cracking down on health spending and the industry generally so conditions are poor. However those conditions were around when Meng bought in.
The last 6 months have also been poor for UCM sales wise. Can't make excuses every quarterly.
Though having said that i'm still buying through low ball bids for a turnaround near the end of the year.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $3.642M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 400000 | 1.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.7¢ | 349988 | 1 |
View Market Depth
| Last trade - 16.21pm 16/07/2025 (20 minute delay) ? |
| UCM (ASX) Chart |
Day chart unavailable